CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Polycystic ovary syndrome - Management
Additional information
- The potential for the long-term use of insulin-sensitizing drugs in women with polycystic ovary syndrome is of interest because hyperinsulinaemia is important in the development of hyperandrogenaemia and disrupted folliculogenesis. Metformin and other insulin-sensitizing drugs decrease insulin secretion and may restore normal endocrinological function, but evidence from good-quality randomized controlled trials is lacking to show they produce clinical benefits.
- Metformin is the most commonly used insulin-sensitizing drug and is the most extensively studied.
- Other insulin-sensitizing drugs include the thiazolidinediones, rosiglitazone and pioglitazone, which are currently being evaluated in randomized controlled trials [Harborne et al, 2003].
© NHS Institute for Innovation and Improvement